Drug Profile
Elamipretide - Stealth BioTherapeutics
Alternative Names: Bendavia; ELA 4; Elamipretide-hydrochloride; Elamipretide-hydrochloride - Stealth Biotherapeutics; MTP 131; Ocuvia; SBT-31; SPI-31; SS-31Latest Information Update: 30 Nov 2023
Price :
$50
*
At a glance
- Originator Cornell University; Institut de recherches cliniques de Montreal
- Developer Stealth BioTherapeutics
- Class Amides; Antihyperglycaemics; Eye disorder therapies; Heart failure therapies; Neuroprotectants; Oligopeptides; Peptides; Small molecules
- Mechanism of Action Cardiolipin modulators; Free radical scavengers; Mitochondrial permeability transition pore inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preregistration Barth syndrome
- Phase III Mitochondrial myopathies
- Phase II Acute kidney injury; Corneal disorders; Dry age-related macular degeneration; Heart failure; Leber's hereditary optic atrophy; Mitochondrial disorders; Reperfusion injury
- Phase I/II Diabetic macular oedema; Friedreich's ataxia
- Preclinical Duchenne muscular dystrophy
- No development reported Chronic heart failure; Diabetes mellitus; Eye disorders; Neurodegenerative disorders
Most Recent Events
- 28 Nov 2023 Stealth BioTherapeutics plans a phase III trial for Dry age-related macular degeneration
- 11 Sep 2023 Stealth BioTherapeutics completes enrolment in its phase III NuPOWER trial for Mitochondrial myopathies in Australia, Germany, Hungary, Italy, Netherlands, New Zealand, Norway, Spain, United Kingdom, USA (SC) (NCT05162768)
- 12 Jun 2023 Stealth BioTherapeutics announces positive end-of-phase II meeting with the US FDA on the development of elamipretide in Dry age-related macular degeneration